Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 13138Triple Negative Breast Neoplasms 1150Neoplasms 750Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

Paclitaxel 2Carboplatin 2talazoparib 1olaparib 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Metastatic Breast Cancer × Breast × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

University of California, San Francisco

Phase 1 Terminated
23 enrolled
BreastOther solid neoplasm

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡